Zacks Investment Research upgraded shares of Capricor Therapeutics Inc (OTCMKTS:CAPR) from a sell rating to a hold rating in a research report released on Tuesday.

According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “

Separately, HC Wainwright began coverage on shares of Capricor Therapeutics in a report on Wednesday, July 6th. They issued a buy rating and a $13.00 price target on the stock.

Shares of Capricor Therapeutics (OTCMKTS:CAPR) opened at 3.45 on Tuesday. The company’s 50 day moving average price is $3.55 and its 200 day moving average price is $3.63. Capricor Therapeutics has a 12-month low of $1.88 and a 12-month high of $5.40. The firm’s market cap is $61.94 million.

Capricor Therapeutics (OTCMKTS:CAPR) last released its quarterly earnings results on Monday, August 15th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.02. Equities research analysts forecast that Capricor Therapeutics will post ($1.04) EPS for the current year.

In other news, major shareholder Sinai Medical Center Cedars bought 312,500 shares of Capricor Therapeutics stock in a transaction that occurred on Wednesday, September 21st. The shares were acquired at an average price of $3.20 per share, with a total value of $1,000,000.00. Following the completion of the purchase, the insider now directly owns 2,904,798 shares in the company, valued at $9,295,353.60. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

An institutional investor recently raised its position in Capricor Therapeutics stock. Vanguard Group Inc. boosted its position in shares of Capricor Therapeutics Inc (OTCMKTS:CAPR) by 25.6% during the second quarter, according to its most recent filing with the SEC. The fund owned 27,975 shares of the company’s stock after buying an additional 5,704 shares during the period. Vanguard Group Inc. owned approximately 0.16% of Capricor Therapeutics worth $111,000 at the end of the most recent reporting period.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.

Get a free copy of the Zacks research report on Capricor Therapeutics (CAPR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Capricor Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc and related companies with's FREE daily email newsletter.